In summary, we have identified the ANLN/EZH2/miR-218-5p/LASP1 signaling axis in pancreatic cancer cells, which provides new insights into the mechanism underlying pancreatic cancer progression and generates a mechanism-based novel framework for developing therapeutics in pancreatic cancer treatment. Here, EZH2 is linked to familial pancreatic carcinoma.